title: Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
abstract: OBJECTIVE
  In the present analysis we examined data from the MTOPS (Medical Therapy of Prostatic Symptoms) trial to determine the effect of long-term finasteride treatment, either alone or in combination with doxazosin, on total prostate volume across the full range of baseline total prostate volume values in men enrolled in this study.
  
  
  METHODS
  In this trial a total of 3,047 patients with lower urinary tract symptoms were randomized to placebo, doxazosin (4 to 8 mg), finasteride (5 mg) or the combination of doxazosin and finasteride (average length of treatment 4.5 years). Total prostate volume was measured by transrectal ultrasound in all patients at baseline, yearly and at study end or at termination of participation.
  
  
  RESULTS
  Long-term treatment with finasteride led to a consistent reduction of approximately 25% in total prostate volume compared to placebo in men with a relatively small prostate (less than 25 to 30 ml), as well as in those with a moderate size (30 to less than 40 ml) or enlarged prostate (40 ml or greater) at baseline.
  
  
  CONCLUSIONS
  In this MTOPS data analysis long-term (more than 4 years) treatment with finasteride, either alone or in combination with doxazosin, led to a consistent, clinically significant reduction in total prostate volume compared to placebo in patients with lower urinary tract symptoms and benign prostatic hyperplasia whose baseline prostate size ranged from relatively small (less than 25 to 30 ml) to enlarged (40 ml or greater).
authors.affiliation: Weill Cornell Medical College, New York, New York 10021, USA. kaplans@med.cornell.edu
authors.forename: Steven A
authors.initials: SA
authors.lastname: Kaplan
authors.forename: Claus G
authors.initials: CG
authors.lastname: Roehrborn
authors.forename: John D
authors.initials: JD
authors.lastname: McConnell
authors.forename: Alan G
authors.initials: AG
authors.lastname: Meehan
authors.forename: Shailaja
authors.initials: S
authors.lastname: Surynawanshi
authors.forename: Jeannette Y
authors.initials: JY
authors.lastname: Lee
authors.forename: Jennifer
authors.initials: J
authors.lastname: Rotonda
authors.forename: John W
authors.initials: JW
authors.lastname: Kusek
authors.forename: Leroy M
authors.initials: LM
authors.lastname: Nyberg
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D017292:Doxazosin / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D018120:Finasteride / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000000981:diagnostic imaging / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D013997:Time Factors; D014463:Ultrasonography
chemical_list: D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride; D017292:Doxazosin